Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; Swiss Group for Clinical Cancer Research. Matter-Walstra K, et al. Among authors: diebold j. J Thorac Oncol. 2016 Nov;11(11):1846-1855. doi: 10.1016/j.jtho.2016.05.032. Epub 2016 Jun 14. J Thorac Oncol. 2016. PMID: 27311996 Free article.
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.
Gautschi O, Zander T, Keller FA, Strobel K, Hirschmann A, Aebi S, Diebold J. Gautschi O, et al. Among authors: diebold j. J Thorac Oncol. 2013 May;8(5):e43-4. doi: 10.1097/JTO.0b013e31828a4d07. J Thorac Oncol. 2013. PMID: 23584301 Free article. No abstract available.
Response to Pembrolizumab in a Patient with Relapsing Thymoma.
Zander T, Aebi S, Rast AC, Zander A, Winterhalder R, Brand C, Diebold J, Gautschi O. Zander T, et al. Among authors: diebold j. J Thorac Oncol. 2016 Dec;11(12):e147-e149. doi: 10.1016/j.jtho.2016.07.018. Epub 2016 Aug 4. J Thorac Oncol. 2016. PMID: 27498287 Free article. No abstract available.
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M. Schmid S, et al. Among authors: diebold j. J Thorac Oncol. 2017 Apr;12(4):681-688. doi: 10.1016/j.jtho.2016.12.003. Epub 2016 Dec 19. J Thorac Oncol. 2017. PMID: 28007627 Free article.
Challenges in the Diagnosis of NTRK Fusion-Positive Cancers.
Gautschi O, Bubendorf L, Leyvraz S, Menon R, Diebold J. Gautschi O, et al. Among authors: diebold j. J Thorac Oncol. 2020 Jul;15(7):e108-e110. doi: 10.1016/j.jtho.2019.05.001. J Thorac Oncol. 2020. PMID: 32593446 Free article. No abstract available.
A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, Diebold J. Gautschi O, et al. Among authors: diebold j. J Thorac Oncol. 2012 Oct;7(10):e23-4. doi: 10.1097/JTO.0b013e3182629903. J Thorac Oncol. 2012. PMID: 22743296 Free article. No abstract available.
623 results